Washout period for immune-modifying drugs before natalizumab therapy.
作者信息
Ilanjian Hilda, Shane Rita
出版信息
Am J Health Syst Pharm. 2008 Jan 1;65(1):18-9. doi: 10.2146/ajhp070334.
PMID:18159033
Abstract
摘要
相似文献
1
Washout period for immune-modifying drugs before natalizumab therapy.
Am J Health Syst Pharm. 2008 Jan 1;65(1):18-9. doi: 10.2146/ajhp070334.
2
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.多发性硬化症患者的那他珠单抗相关性进行性多灶性白质脑病：28 例病例的经验教训。
Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4.
3
Balancing risk and reward: the question of natalizumab.权衡风险与收益：那他珠单抗的问题
Ann Neurol. 2009 Sep;66(3):A7-8. doi: 10.1002/ana.21873.
4
Quantitative risk-benefit analysis of natalizumab.那他珠单抗的定量风险效益分析。
Neurology. 2008 Jul 29;71(5):357-64. doi: 10.1212/01.wnl.0000319648.65173.7a.
5
Use of natalizumab in multiple sclerosis: current perspectives.那他珠单抗在多发性硬化中的应用：当前观点。
Expert Opin Biol Ther. 2016 Sep;16(9):1151-62. doi: 10.1080/14712598.2016.1213810. Epub 2016 Jul 27.
6
Natalizumab in Multiple Sclerosis: Long-Term Management.那他珠单抗治疗多发性硬化症：长期管理
Int J Mol Sci. 2017 Apr 29;18(5):940. doi: 10.3390/ijms18050940.
7
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.多发性硬化症、那他珠单抗治疗与进行性多灶性白质脑病
Curr Opin Neurol. 2006 Aug;19(4):341-9. doi: 10.1097/01.wco.0000236612.66839.a2.
8
Multiple sclerosis, natalizumab, and PML: helping patients decide.多发性硬化症、那他珠单抗和 PML：帮助患者做出决策。
Cleve Clin J Med. 2011 Nov;78 Suppl 2:S18-23. doi: 10.3949/ccjm.78.s2.05.
9
Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.识别接受那他珠单抗治疗的多发性硬化症患者发生进行性多灶性白质脑病风险的免疫生物标志物。
J Neuroimmunol. 2014 Dec 15;277(1-2):6-12. doi: 10.1016/j.jneuroim.2014.10.011. Epub 2014 Nov 3.
10
PML: underdiagnosed in MS patients on natalizumab.进行性多灶性白质脑病：在使用那他珠单抗的多发性硬化症患者中诊断不足。
Lancet Neurol. 2010 Jun;9(6):564; author reply 564-5. doi: 10.1016/S1474-4422(10)70122-8.
Zotero 插件